Development of first Generation COVID-19 Vaccines: State-of the-Art Technologies and future Implications!

Main Article Content

Larry L Mweetwa Derrick D Tlhoiwe Tumelo Tlhoiwe Kabo Osmas Tshiamo Sody Mweetwa Munsaka Thatoyaone J Kenaope Getrude Mothibe Ogorogile Mokate Emmanuel T Oluwabusola

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or Coronavirus was initially detected in Wuhan China in December 2019 and has subsequently resulted in the COVID-19 pandemic. The disease presents asymptomatically in some of individuals yet also causes symptoms ranging from those associated with influenza and pneumonia, acute respiratory distress syndrome (ARDS) and even death. The world is currently relying on physical (social) distancing, hygiene and repurposed medicines; however, it was predicted that an effective vaccine will be necessary to ensure comprehensive protection against COVID-19. There was a global effort to develop an effective vaccine against SARS-CoV-2 with approximately 300 vaccines in clinical trials, and over 200 more in different stages of development and anticipated that their success will change research clinical trials processes. Although every one of these vaccines comes with its own particular set of characteristics and difficulties, they were all developed as a direct result of research and development efforts that were carried out on a scale that had never been seen before. It is the first time in the history of vaccination that a worldwide immunization campaign has begun during a time of severe pandemic activity that is defined by high virus transmission. This achievement marks an important milestone in the history of vaccination. More than anything else, the most important aspect of the new game change in drug design is that the traditional drug discovery rules have been rewritten. This is especially significant for the development of vaccines, as it is possible for all clinical trials to be accelerated, which would bring a vaccine or drug molecule to market within a year rather than the traditional fifteen years for each phase of drug clinical trials. This review provides insight in respect to first generation COVID-19 vaccines, which were in clinical use as of December 2020 and focused on the Pfizer/ BioNTech/Fosun, Moderna mRNA-1273, Johnson and Johnson and AstraZeneca/Oxford AZD1222 vaccines.

Keywords: Coronavirus, Vaccines, AstraZeneca, Moderna (mRNA-1273), Pfizer, Johnson and Johnson, Gamaleya, Sinopharm, Viral Vector, Sputnik

Article Details

How to Cite
MWEETWA, Larry L et al. Development of first Generation COVID-19 Vaccines: State-of the-Art Technologies and future Implications!. Medical Research Archives, [S.l.], v. 10, n. 9, sep. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3027>. Date accessed: 24 may 2024. doi: https://doi.org/10.18103/mra.v10i9.3027.
Section
Research Articles

References

1. Randolph H, Barreiro L. Herd Immunity: Understanding COVID-19. Immunity. 2020;52(5):737-741. doi:10.1016/j.immuni.2020.04.012
2. Jung F, Krieger V, Hufert F, Küpper J. Herd immunity or suppression strategy to combat COVID-19. Clin Hemorheol Microcirc. 2020;75(1):13-17. doi:10.3233/ch-209006
3. Netea M, Joosten L, Latz E et al. Trained immunity: A program of innate immune memory in health and disease. Science (1979). 2016;352(6284). doi:10.1126/science.aaf1098
4. Grifoni A, Weiskopf D, Ramirez S et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181(7):1489-1501.e15. doi:10.1016/j.cell.2020.05.015
5. Johnson Z, Zinser E, Coe A, McNulty N, Woodward E, Chisholm S. Niche Partitioning Among Prochlorococcus Ecotypes Along Ocean-Scale Environmental Gradients. Science (1979). 2006;311(5768):1737-1740. doi:10.1126/science.1118052
6. Mellet J, Pepper M. A COVID-19 Vaccine: Big Strides Come with Big Challenges. Vaccines (Basel). 2021;9(1):39. doi:10.3390/vaccines9010039
7. Anderson E, Rouphael N, Widge A et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New England Journal of Medicine. 2020;383(25):2427-2438. doi:10.1056/nejmoa2028436
8. Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1). doi:10.1038/s41392-020-00352-y
9. Polack F, Thomas S, Kitchin N et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 2020;383(27):2603-2615. doi:10.1056/nejmoa2034577
10. Biorender Immunogenecity to SARS-CoV-2 2021.
11. Han S. Clinical vaccine development. Clin Exp Vaccine Res. 2015;4(1):46. doi:10.7774/cevr.2015.4.1.46
12. Singh K, Mehta S. The clinical development process for a novel preventive vaccine: An overview. J Postgrad Med. 2016;62(1):4. doi:10.4103/0022-3859.173187
13. Corbett K, Edwards D, Leist S et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567-571. doi:10.1038/s41586-020-2622-0
14. Sharma O, Sultan A, Ding H, Triggle C. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.585354
15. Sharma O, Sultan A, Ding H, Triggle C. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.585354
16. Conforti A, Marra E, Roscilli G, Palombo F, Ciliberto G, Aurisicchio L. Are Genetic Vaccines the Right Weapon against COVID-19?. Molecular Therapy. 2020;28(7):1555-1556. doi:10.1016/j.ymthe.2020.06.007
17. Sharpe H, Gilbride C, Allen E et al. The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. Immunology. 2020;160(3):223-232. doi:10.1111/imm.13222
18. Triggle C, Bansal D, Farag E, Ding H, Sultan A. COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions. mSphere. 2020;5(3). doi:10.1128/msphere.00317-20
19. Mulligan M, Lyke K, Kitchin N et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589-593. doi:10.1038/s41586-020-2639-4
20. Graham S, McLean R, Spencer A et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. 2020. doi:10.1101/2020.06.20.159715
21. Folegatti P, Ewer K, Aley P et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020;396(10249):467-478. doi:10.1016/s0140-6736(20)31604-4
22. Tebas P, Yang S, Boyer J et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine. 2021;31:100689. doi:10.1016/j.eclinm.2020.100689
23. Funk C, Laferrière C, Ardakani A. A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Front Pharmacol. 2020;11. doi:10.3389/fphar.2020.00937
24. Baden L, El Sahly H, Essink B et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine. 2021;384(5):403-416. doi:10.1056/nejmoa2035389
25. Joint Committee On Vaccination And Immunisation (JCVI) Optimising The COVID-19 Vaccination Programme For Maximum Short-Term Impact Short Statement From The Joint Committee On Vaccination And Immunisation (JCVI); 2020;.; 2022.
26. Janssen Vaccines & Prevention B.V A Randomised, Double-Blind, Placebo-Controlled Phase 3 Study To Assess The Efficacy And Safety Of Ad26.COV2. A For The Prevention Of SARS-Cov-2-Mediated COVID-19 In Adults Aged 18 Years And Older. Available Online: Https://Clinicaltrials.Gov/Ct2/Show/NCT04505722..; 2022.
27. Johnson & Johnson Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints In Interim Analysis Of Its Phase 3 ENSENBLE Trial. Available Online: Https://Www.Jnj.Com/Johnson-Johnson-Announces-Single-Shot-Janssen-Covid-19-Vaccine-Candidate-Met-Primary-Endpoints-In-Endpoints-Interim-Analysis-Of-Its-Phase-3-Ensemble-Trial#_Edn1..; 2022.
28. Logunov D, Dolzhikova I, Zubkova O et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 2020;396(10255):887-897. doi:10.1016/s0140-6736(20)31866-3
29. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. The Lancet. 2021;397(10275):642-643. doi:10.1016/s0140-6736(21)00191-4
30. Palacios R, Patiño E, de Oliveira Piorelli R et al. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1). doi:10.1186/s13063-020-04775-4
31. Kim J, Marks F, Clemens J. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27(2):205-211. doi:10.1038/s41591-021-01230-y
32. Tanveer F, Khalil A, Ali M, Shinwari Z. Ethics, pandemic and environment; looking at the future of low middle income countries. Int J Equity Health. 2020;19(1). doi:10.1186/s12939-020-01296-z
33. Djalante R, Shaw R, DeWit A. Building resilience against biological hazards and pandemics: COVID-19 and its implications for the Sendai Framework. Progress in Disaster Science. 2020;6:100080. doi:10.1016/j.pdisas.2020.100080
34. Monrad J. Ethical considerations for epidemic vaccine trials. J Med Ethics. 2020;46(7):465-469. doi:10.1136/medethics-2020-106235
35. UN Environment Programme COVID-19 vaccine could revolutionize cold storage around the world; 2020;2022
36. UN Sustainable Development Group (UNSDG) Responding to the socio-economic impacts of COVID-19. ; 2020;2022
37. Forni G, Mantovani A. COVID-19 vaccines: where we stand and challenges ahead. Cell Death & Differentiation. 2021;28(2):626-639. doi:10.1038/s41418-020-00720-9
38. Covid-19 Vaccination; Where Do We Stand?. Journal of Saidu Medical College Swat. 2021. doi:10.52206/jsmc.2021.11.2.61-62
39. Shen A, Hughes IV R, DeWald E, Rosenbaum S, Pisani A, Orenstein W. Ensuring Equitable Access To COVID-19 Vaccines In The US: Current System Challenges And Opportunities. Health Affairs. 2021;40(1):62-69. doi:10.1377/hlthaff.2020.01554
40. Wakabayashi M, Ezoe S, Yoneda M, Katsuma Y, Iso H. Global landscape of the COVID-19 vaccination policy: Ensuring equitable access to quality-assured vaccines. GHM Open. 2021. doi:10.35772/ghmo.2021.01029
41. Hotez P, Bottazzi M. Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. Annu Rev Med. 2022;73(1):55-64. doi:10.1146/annurev-med-042420-113212
42. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. International Journal of Infectious Diseases. 2022;114:252-260. doi:10.1016/j.ijid.2021.11.009
43. Alu A, Chen L, Lei H, Wei Y, Tian X, Wei X. Intranasal COVID-19 vaccines: From bench to bed. EBioMedicine. 2022;76:103841. doi:10.1016/j.ebiom.2022.103841
44. Kaplonek P, Cizmeci D, Fischinger S et al. mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. Sci Transl Med. 2022;14(645). doi:10.1126/scitranslmed.abm2311
45. Nohynek H, Wilder-Smith A. Does the World Still Need New Covid-19 Vaccines?. New England Journal of Medicine. 2022;386(22):2140-2142. doi:10.1056/nejme2204695
46. Vuong Q, Le T, La V et al. Covid-19 vaccines production and societal immunization under the serendipity-mindsponge-3D knowledge management theory and conceptual framework. Humanities and Social Sciences Communications. 2022;9(1). doi:10.1057/s41599-022-01034-6
47. Marra A, Kobayashi T, Suzuki H et al. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis. Journal of Infection. 2022;84(3):297-310. doi:10.1016/j.jinf.2021.12.035